First clinical trials expected in 2008

Jersey City, New Jersey—June 28, 2007—Quantum Genomics Corp. (QGC), a global biotech company developing new drugs for metabolic and cardiovascular diseases, announced partnership agreements with Inserm, the French national institute for health and medical research and the CNRS, France’s national center for scientific research, and University Paris Descartes. The agreement brings together some of the best scientific skills in the field of cardiovascular diseases from two leading life science research organizations and a premier university along with biotechnology business experience from QGC, to successfully co-develop innovative drugs.

The agreement covers a lead molecule derived from discoveries by teams led respectively by Dr Catherine Llorens-Cortes, director of Inserm Unit 691, based in the Collège de France and by Prof. Bernard P. Roques at Inserm Unit 640, itself based in the University of Paris Descartes.

The purpose of the agreement is to co-develop innovative drugs for hypertension and related cardiovascular diseases. Under the terms of the contract, QGC acquires rights to exploit three patents and associated know-how. Inserm and CNRS will work on the physiopathology, chemistry and the understanding of the compound’s mechanism of action whereas QGC will handle preclinical and clinical development and regulatory aspects.

The first lead molecule to be developed will be QGC001, a new chemical entity. This compound acts according to a new biological mechanism with a huge potential to facilitate control of blood pressure in patients who are resistant to currently available anti-hypertension drugs. QGC expects to start the first clinical trial in humans in 2008.

“We are delighted to be partnering with Inserm and CNRS, two of the world’s leading healthcare research organizations,” said Lionel Ségard, Chairman and CEO of QGC. “This project lets QGC demonstrate its ability to develop new drugs in compliance with international regulatory guidelines. It also significantly reinforces QGC’s potential in R&D in the field of cardiovascular diseases.”

“This partnership with QGC gives us an excellent opportunity to accelerate the pre-clinical and clinical development of a project based on work carried out in our labs in close cooperation with Bernard Roques’ team,” said Catherine Llorens Cortes, director of Inserm Unit 691.

Cardiovascular diseases are one of the main causes of death in humans. Hypertension in particular is one of the major determining factors in premature death. The risk of myocardial infarction, stroke, kidney failure, heart failure or other complications doubles with every 20/10mmHg rise in blood pressure. At least 30% of people have hypertension. Hundreds of millions of people worldwide suffer from hypertension complications despite medical advice on food and health habits and the existence of several treatments. The market for hypertensive drugs is expected to double between 2005 and 2010 .